Encapsulation and pH-responsive release of bortezomib by dopamine grafted hyaluronate nanogels

Liu, Lei; Luan, Shujuan; Zhang, Chunli; Wu, Rui; Zhang, Yanan; Zhang, Mingjie; Sheng, Qianli; Hân, Gia; Wang, Tianshun; Song, Shiyong

doi:10.1016/j.ijbiomac.2021.04.161

Cited by 15 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentration of Cur in the samples was measured using a fluorescence spectrophotometer (Ex = 442 nm, Em = 475 nm) (F-7000, Hitachi High-Tech, Japan). The cumulative release of Cur was calculated by the following formula: ( Liu et al, 2021a )

Where: V i is the volume of samples (ml), V 0 is the total volume of the release medium (ml), C i is the drug concentration of the samples (mg/ml), m is the initial amount of the Cur in the dialysis bags (mg), and n is the number of samples (n > 0).…”

Section: Methodsmentioning

confidence: 99%

Section: In Vitro Releasementioning

confidence: 99%

“…To improve the transdermal penetration and the retention of drugs in the skin, various nanocarriers (such as solid lipid nanoparticles, ethosomes, and emulsions) have been developed to improve topical transdermal delivery ( Ilic et al, 2021 ; El-Hashemy, 2022 ; Niu et al, 2022 ). Among various types of nanocarriers, nanogels have attracted increasing attention due to their unique advantages, including great colloidal stability, tunable size, large surface area for biological coupling, and porous structure for loading large amounts of drugs ( Sivaram et al, 2015 ; Liu et al, 2021a ). In addition, due to the unique structure, nanogels can bind a large amount of water to moisturize and enhance the hydration of the stratum corneum, which is conducive to its role in the field of transdermal drug delivery ( Kim et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin

et al. 2022

View full text Add to dashboard Cite

The present study focused on the development of Cur-loaded SOHA nanogels (Cur-SHNGs) to enhance the topical administration of Cur. The physiochemical properties of Cur-SHNGs were characterized. Results showed that the morphology of the Cur-SHNGs was spherical, the average size was 171.37 nm with a zeta potential of −13.23 mV. Skin permeation experiments were carried out using the diffusion cell systems. It was found that the skin retention of Cur-SHNGs was significantly improved since it showed the best retention value (0.66 ± 0.17 μg/cm2). In addition, the hematoxylin and eosin staining showed that the Cur-SHNGs improved transdermal drug delivery by altering the skin microstructure. Fluorescence imaging indicated that Cur-SHNGs could effectively deliver the drug to the deeper layers of the skin. Additionally, Cur-SHNGs showed significant analgesic and anti-inflammatory activity with no skin irritation. Taken together, Cur-SHNGs could be effectively used for the topical delivery of therapeutic drugs.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: In Vitro Releasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Liu et al developed a novel method for the encapsulation of BTZ, in which BTZ was loaded with dopamine-grafted HA nanogel via a borate ester bond [ 122 ]. Owing to the location of dopamine on the skeleton structure of the nanogel (NSS-BTZ), more BTZ loading was achieved (≤8.58%).…”

Section: Research Progress Regarding Btz-based Nanoformulationsmentioning

confidence: 99%

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations

et al. 2021

View full text Add to dashboard Cite

Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma. Moreover, its use in the treatment of other hematological cancers and solid tumors has been investigated in numerous clinical trials and preclinical studies. Nevertheless, the applications of BTZ are limited due to its insufficient specificity, poor permeability, and low bioavailability. Therefore, in recent years, different BTZ-based drug delivery systems have been evaluated. In this review, we firstly discussed the functions of proteasome inhibitors and their mechanisms of action. Secondly, the properties of BTZ, as well as recent advances in both clinical and preclinical research, were reviewed. Finally, progress in research regarding BTZ-based nanoformulations was summarized.

show abstract

“…[ 2 ] Chemotherapy is the main approach used to inhibit breast cancer growth, reduce the occurrence of skeletal‐related events, and improve patient quality of life. [ 3 ] However, such treatments have failed to improve the clinical outcomes of breast cancer patients because of their significant side effects including drug resistance, non‐specific biodistributions, and clinical complications. [ 4 ] Therefore, the development of innovative and effective anti‐tumor therapeutic methods would greatly benefit the clinical treatment of breast cancer bone metastases.…”

Section: Introductionmentioning

confidence: 99%

NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases

Sun

Zhang

et al. 2022

Advanced Science

View full text Add to dashboard Cite

To improve bone metastases treatment efficacy, current strategies are focused on the integration of chemotherapy with phototheranostic. However, the success of phototheranostic approaches is hampered by the limited tissue penetration depth of near-infrared-I (NIR-I) light (700-900 nm). In this study, a NIR-II (1000-1700 nm) excitation phototheranostic (BTZ/Fe 2+ @BTF/ALD) is presented for NIR-II fluorescence imaging and NIR-II photoacoustic imaging-guided NIR-II photothermal therapy (PTT), chemotherapy, and chemodynamic therapy (CDT) of breast cancer bone metastases. This phototheranostic is developed by integrating a dopamine-modified NIR-II absorbing donor-acceptor-donor small molecule (BBT-FT-DA), the boronate anticancer drug bortezomib (BTZ), and Fe 2+ ions, as CDT catalysts, into an amphiphilic PEGylated phospholipid modified with the bone-targeting ligand alendronate. In acidic and hydrogen peroxide (H 2 O 2 ) over expression tumor microenvironment, the boronate-catechol linkage is cleaved and BTZ and Fe 2+ ions are released to initiate the Fenton reaction, that is, chemotherapy and CDT, respectively, are initialized. It is confirmed using the murine 4T1 bone metastasis model that BTZ/Fe 2+ @BTF/ALD significantly suppresses the progression of tumor cells in the bone tissue via a synergistic NIR-II PTT/chemotherapy/CDT effect. Overall, this work provides fresh insights to guide the development of NIR-II phototheranostics for breast cancer bone metastases.

show abstract

Encapsulation and pH-responsive release of bortezomib by dopamine grafted hyaluronate nanogels

Cited by 15 publications

References 40 publications

Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin

Silk peptide-hyaluronic acid based nanogels for the enhancement of the topical administration of curcumin

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations

NIR‐II Excitation Phototheranostic Platform for Synergistic Photothermal Therapy/Chemotherapy/Chemodynamic Therapy of Breast Cancer Bone Metastases

Contact Info

Product

Resources

About